Premium
Transporter Pharmacogenetics and Statin Toxicity
Author(s) -
Niemi M
Publication year - 2010
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2009.197
Subject(s) - pharmacogenetics , transporter , pharmacology , statin , efflux , pharmacokinetics , solute carrier family , slco1b1 , clinical pharmacology , myopathy , toxicity , medicine , organic anion transporter 1 , chemistry , gene , biochemistry , genotype
Polymorphisms in transporter genes can have profound effects on statin pharmacokinetics. In particular, a common genetic variant of organic anion–transporting polypeptide 1B1 reduces the hepatic uptake of many statins, increasing the risk of statin‐induced myopathy. Similarly, genetically impaired adenosine triphosphate (ATP)‐binding cassette G2 transporter efflux activity results in a marked increase in systemic exposure to various statins. Importantly, the effects of these genetic polymorphisms differ depending on the specific statin that is used. This provides a rational basis for the individualization of lipid‐lowering therapy. Clinical Pharmacology & Therapeutics (2010) 87 1, 130–133. doi: 10.1038/clpt.2009.197